Leukemic transformation in myeloproliferative neoplasms (MPN), also referred to as “blast-
phase MPN”, is the most feared disease complication, with incidence estimates of 1–4% for …

Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders
characterized by activated Janus kinase (JAK)–signal transducer and activator of …

The primary objective of treatment in myelofibrosis (MF) is prolongation of life, which is
currently accomplished only by allogeneic hematopoietic stem cell transplantation (AHSCT) …

Janus kinase (JAK) 2 inhibitors are now part of the therapeutic armamentarium for primary
and secondary myelofibrosis (MF). Patients with MF endure shortened survival and poor …

Abstract Disease Overview Primary myelofibrosis (PMF) is a myeloproliferative neoplasm
(MPN) characterized by stem cell‐derived clonal myeloproliferation that is often but not …

Contemporary risk models in primary myelofibrosis (PMF) include the mutation (MIPSS70)
and mutation/karyotype enhanced (MIPSS70 plus/v2. 0) international prognostic scoring …

The application of genomic techniques, including cytogenetics and DNA sequencing, to
decipher the molecular landscape of patients with myeloproliferative neoplasms (MPNs) has …

Momelotinib for myelofibrosis: 12-year survival data and retrospective comparison to
ruxolitinib Momelotinib for myelofibrosis: 12-year survival data and retrospective …

Abstract Purpose of Review Philadelphia-negative myeloproliferative neoplasms (MPNs)
include polycythemia vera (PV), essential thrombocythemia (ET), prefibrotic (pre-), and overt …

Momelotinib is an ATP-competitive small molecule inhibitor of Janus kinase proteins (JAKi),
including JAK1, JAK2, JAK3, and TYK2; its other clinically relevant targets include activin A …